Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...

Complex life began to develop earlier, and over a longer span of time, than previously believed, a new study has revealed. The research sheds new light on the conditions needed for early organisms to ...

atai Life Sciences (NASDAQ:ATAI) stock rose after positive results from a mid-stage study exploring a two-dose treatment plan using BPL-003, a nasal spray form of mebufotenin benzoate, for patients ...